R-DTI: Drug Target Interaction Prediction Based on Second-Order Relevance Exploration

Yang Hua, Tianyang Xu, Xiaoning Song, Zhenhua Feng, Rui Wang, Wenjie Zhang, Xiaojun Wu

Introduction

Predicting interactions between drug molecules and target proteins is a fundamental task in virtual drug screening. Traditional deep learning approaches for Drug-Target Interaction (DTI) prediction often struggle with two primary challenges: the structural complexity of proteins and the "feature gap" between protein and drug representations. While proteins are complex 3D entities, models frequently rely on 1D amino acid sequences, failing to capture essential spatial topologies. Furthermore, simple concatenation or multiplication of disparate feature spaces often leads to model bias, where the predictor over-relies on one modality (typically the protein) at the expense of the other, resulting in poor generalization to unseen targets.

Methodology: Exploring Second-Order Relevance

R-DTI introduces a framework centered on Riemannian manifold geometry to address these hurdles. The core innovation lies in moving from "first-order" feature matching to "second-order" relevance exploration.

Conceptual overview of Riemannian structural features and second-order relevance.

Feature Extraction

The R-DTI architecture employs specialized extractors for both proteins and drugs:

  • Protein Feature Extractor: To preserve spatial relationships without requiring explicit 3D data during inference, the model uses a pre-trained extractor that represents amino acids as Symmetric Positive Definite (SPD) matrices. These matrices capture the covariance of atomic properties, effectively modeling the protein's manifold structure.
  • Drug Feature Extractor: This component combines textual semantic features from SMILES-Bert with structural features derived from a Molecular Graph Attention (M-GAT) block, ensuring a comprehensive representation of the drug's molecular graph.

Riemannian Classifier and Auxiliary Training

The "second-order" relevance is captured by projecting combined drug and protein features into a unified Riemannian space. Unlike standard Euclidean classifiers, the Riemannian classifier calculates the relationship between feature sets, creating a stable interaction map. To facilitate training—given the mathematical complexity of Riemannian gradients—an auxiliary 1D CNN classifier is utilized to guide the feature extractors.

Detailed architecture of the R-DTI framework.

Key Results and Insights

R-DTI was evaluated across six major benchmarks, including BindingDB and DrugBank, consistently outperforming existing state-of-the-art (SOTA) methods.

  • Performance: On BindingDB, R-DTI achieved an AUC-ROC of 0.983, a 1.4% improvement over previous benchmarks. On DrugBank, it reached 0.914 AUC-ROC.
  • Generalization: The model demonstrated superior stability in "unseen target" scenarios. By focusing on the relationship between drug and target features within a unified manifold, R-DTI avoids the common pitfall of memorizing specific protein sequences.
  • Interpretability: Visualization of Riemannian features indicated that the model naturally highlights focal regions corresponding to potential biological binding sites, even without explicit supervision.

Conclusion

By leveraging Riemannian geometry to explore second-order relevance, R-DTI provides a robust solution to the structural complexity and feature bias inherent in DTI prediction. While the computational cost of manifold operations remains a consideration, the significant gains in accuracy and generalization mark a substantial step forward for computational drug discovery.

Summary updated

Abstract

Drug Target Interaction (DTI) prediction has witnessed promising performance boosts accompanied by advanced multimodal feature extraction. However, existing approaches suffer from two main difficulties. First, the complex protein structures cannot be well represented by current protein-sequence-based feature extractors. Second, the gap between protein and drug features increases the vulnerability of the obtained classifier thus degrading the prediction robustness. To address these issues, we propose a novel R-DTI method by exploring the second-order relevance in both protein structural feature extraction and DTI prediction phases. Specifically, we construct a pre-trained structural feature extractor that mines the atomic relevance of each amino acid. Then, an inter-feature structure-preserved Riemannian network is designed to expand the existing protein extraction patterns. To improve the prediction robustness, we also develop a Riemannian classifier that uses the second-order protein-drug relevance with a unified feature space. Extensive experimental results demonstrate the merits and superiority of our R-DTI against the state-of-the-art, achieving 1.4% and 1.9% higher AUC-ROC on the BindingDB and DrugBank datasets, respectively.
BibTeX
@inproceedings{hua2025r,
  author = {Yang Hua and Tianyang Xu and Xiaoning Song and Zhenhua Feng and Rui Wang and Wenjie Zhang and Xiaojun Wu},
  title = {{R-DTI: Drug Target Interaction Prediction Based on Second-Order Relevance Exploration}},
  booktitle = {AAAI Conference on Artificial Intelligence},
  year = {2025},
  doi = {10.1609/aaai.v39i16.33909},
}
Figure